AgingResearch.NewsJoin free

Agomab Spain

CompanySpain

Agomab Spain develops one asset, in phase 2 (AGMB-447 in idiopathic pulmonary fibrosis). Mostly small molecule acting on TGFBR1; based in Spain.

1
Asset
Furthest stage
Phase 2
1
Trial
2
Signals

Pipeline

1

  • AGMB-447

    Inhaled small molecule ALK5 (TGF-beta type I receptor) inhibitor targeting lung fibrosis.

    Phase 2, Small molecule, TGFBR1, idiopathic pulmonary fibrosis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials1
  • Signals2
  • Similar companies6

Intelligence